NxStage Medical, Inc. (NASDAQ:NXTM) SVP Matthew W. Towse sold 4,300 shares of the company’s stock in a transaction dated Thursday, April 20th. The shares were sold at an average price of $27.28, for a total value of $117,304.00. Following the completion of the sale, the senior vice president now directly owns 29,637 shares of the company’s stock, valued at $808,497.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
NxStage Medical, Inc. (NASDAQ:NXTM) traded up 2.63% during mid-day trading on Thursday, reaching $28.09. The company had a trading volume of 540,079 shares. The firm’s 50-day moving average is $27.17 and its 200-day moving average is $26.19. NxStage Medical, Inc. has a one year low of $15.30 and a one year high of $29.99. The firm’s market capitalization is $1.83 billion.
NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Tuesday, February 28th. The medical device company reported ($0.02) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.02). The firm earned $93.01 million during the quarter, compared to the consensus estimate of $91.82 million. NxStage Medical had a negative return on equity of 2.97% and a negative net margin of 1.61%. The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.04) earnings per share.
ILLEGAL ACTIVITY NOTICE: This story was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.wkrb13.com/markets/2065569/nxstage-medical-inc-nxtm-svp-matthew-w-towse-sells-4300-shares.html.
A number of large investors have recently made changes to their positions in NXTM. Capital Impact Advisors LLC bought a new stake in shares of NxStage Medical during the first quarter valued at about $1,194,000. Teachers Advisors LLC increased its stake in shares of NxStage Medical by 3.8% in the fourth quarter. Teachers Advisors LLC now owns 116,182 shares of the medical device company’s stock valued at $3,045,000 after buying an additional 4,257 shares during the period. Norges Bank bought a new stake in shares of NxStage Medical during the fourth quarter valued at about $11,841,000. Fortaleza Asset Management Inc. increased its stake in shares of NxStage Medical by 2.5% in the fourth quarter. Fortaleza Asset Management Inc. now owns 8,055 shares of the medical device company’s stock valued at $211,000 after buying an additional 195 shares during the period. Finally, Clough Capital Partners L P bought a new stake in shares of NxStage Medical during the fourth quarter valued at about $532,000. Institutional investors and hedge funds own 97.26% of the company’s stock.
NXTM has been the subject of a number of recent analyst reports. Jefferies Group LLC upped their price target on NxStage Medical to $38.00 and gave the company a “buy” rating in a research note on Monday, February 6th. Zacks Investment Research cut NxStage Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 5th. Canaccord Genuity set a $31.00 price target on NxStage Medical and gave the company a “buy” rating in a research note on Monday, January 23rd. Finally, Northland Securities reaffirmed a “buy” rating and issued a $35.00 price target on shares of NxStage Medical in a research note on Monday, April 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $29.67.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065569/nxstage-medical-inc-nxtm-svp-matthew-w-towse-sells-4300-shares.html
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.